Keros shareholders approve 2026 meeting items
Keros Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026.
Rhea-AI Filing Summary
Keros Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. A quorum was present and stockholders voted on director elections, auditor ratification and an advisory say-on-pay resolution.
Stockholders elected Jean-Jacques Bienaimé and Charles Newton as directors to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified. They also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the April 22, 2026 proxy statement.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Bienaimé: 10,093,559.27 votes
Votes for Newton: 14,716,598 votes
Auditor ratification for votes: 16,708,279.27 votes
+2 more
5 metrics
Votes for Bienaimé
10,093,559.27 votes
Election of director Jean-Jacques Bienaimé, Proposal 1
Votes for Newton
14,716,598 votes
Election of director Charles Newton, Proposal 1
Auditor ratification for votes
16,708,279.27 votes
Ratification of Deloitte & Touche LLP, Proposal 2
Say-on-pay for votes
14,273,625.27 votes
Advisory approval of executive compensation, Proposal 3
Broker non-votes on pay
2,243,514 votes
Broker non-votes on Proposal 3
Key Terms
Annual Meeting of Stockholders, independent registered public accounting firm, non-binding advisory basis, broker non-votes
4 terms
Annual Meeting of Stockholders regulatory
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present"
independent registered public accounting firm regulatory
"Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding advisory basis regulatory
"to approve, on an advisory basis, the compensation of the Company’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
broker non-votes regulatory
"Votes For | Votes Against | Votes Abstain | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Keros Therapeutics (KROS) stockholders vote on at the 2026 Annual Meeting?
Stockholders voted on three items: electing two directors to serve until the 2029 meeting, ratifying Deloitte & Touche LLP as auditor for 2026, and approving, on an advisory basis, the compensation of named executive officers as described in the April 22, 2026 proxy statement.
Who was elected to the Keros Therapeutics (KROS) board of directors in 2026?
Jean-Jacques Bienaimé and Charles Newton were elected as directors to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified. Their elections were approved by stockholders at the 2026 Annual Meeting where a quorum was present.
Which auditing firm did Keros Therapeutics (KROS) stockholders ratify for fiscal 2026?
Stockholders ratified Deloitte & Touche LLP as Keros Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received substantially more votes for than against, and there were no broker non-votes reported for this proposal.
Was Keros Therapeutics (KROS) executive compensation approved by stockholders in 2026?
Yes, stockholders approved, on a non-binding advisory basis, the compensation of Keros Therapeutics’ named executive officers. The say-on-pay vote corresponded to Proposal 3 and was based on the disclosures in the April 22, 2026 definitive proxy statement filed with the SEC.
How did broker non-votes affect the Keros Therapeutics (KROS) 2026 meeting results?
Broker non-votes were reported for the director elections and the advisory vote on executive compensation, but none for the auditor ratification. These broker non-votes counted toward the quorum but were not treated as votes for or against those specific proposals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
